Journals / Eurasian Journal of Medicine / 2011 / Cilt: 43 - Sayı: 3

Anorektal malign melanomada multimodalite tedavi; bir vaka raporu ve literatür analizi

Pages
189–191
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aim to discuss combined treatment modalities for ARM in light of the pertinent literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Anorectal melanoma represents approximately 0.2-1% of all malignant melanomas and has a poor prognosis, with a median survival of 8 to 23 months after the time of diagnosis.
📊
Key Findings & Data:Here, we present the case of a 54-year-old female with anorectal melanoma that had metastasized to an inguinal lymph node.
💡
Conclusion & Impact:We aim to discuss combined treatment modalities for ARM in light of the pertinent literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Anorectal melanoma represents approximately 0.2-1% of all malignant melanomas and has a poor prognosis, with a median survival of 8 to 23 months after the time of diagnosis. The typical treatment modalities include surgery, radiotherapy and chemotherapy. The particular approach taken depends on the patient’s status and disease stage. Although there are different treatment options for this rare condition, there are not enough studies on multimodality treatment. Here, we present the case of a 54-year-old female with anorectal melanoma that had metastasized to an inguinal lymph node. She underwent local excision of the rectal mass and inguinal lymph-node dissection. Temozolomide treatment was started after radiotherapy and was given for 24 months. Follow-up revealed that the patient has been doing well with no signs of recurrence three years after the completion of treatment. We aim to discuss combined treatment modalities for ARM in light of the pertinent literature.

🔖

Cite This Article

DİZDAR, Ö., ÇELİK, İ., BULUT, N., TAPAN, U. (2022). Anorektal malign melanomada multimodalite tedavi; bir vaka raporu ve literatür analizi. Eurasian Journal of Medicine, Cilt: 43 - Sayı: 3, 189–191. https://ajindex.com/articles/509283

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Tomicic J, Wanebo HJ. Mucosal melanomas. Surg Clin North Am 2003; 83: 237-52
  2. Weinstock MA. Epidemiology and prognosis of anorectal melanoma. Gastroenterology 1993; 104: 174-8
  3. Droesch JT, Flum DR, Mann GN. Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma? Am J Surg 2009; 189: 446-9. [CrossRef] 4. Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol 2002; 20: 4555-8
  4. Krengli M, Jereczek-Fossa BA, Kaanders JH, Masini L, Beldi D, Orecchia R. What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck? Crit Rev Oncol Hematol 2008; 65: 121-8
  5. NCCN Clinical Practice Guidelines in Oncology. Melanoma. Version 2.2012. http://www.nccn.org/professionals/physician_ gls/pdf/melanoma.pdf. Date last updated: May 3 2011. Date last accessed: June 1 2011
  6. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66
  7. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000; 6: 2585-97
  8. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106: 1431-42
  9. Kim KB, Sanguino AM, Hodges C, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer 2004; 100: 147.